Previous Close | 221.65 |
Open | 220.44 |
Bid | 0.00 x 800 |
Ask | 0.00 x 3000 |
Day's Range | 212.02 - 222.95 |
52 Week Range | 158.38 - 245.48 |
Volume | |
Avg. Volume | 501,961 |
Market Cap | 9.956B |
Beta (5Y Monthly) | 0.53 |
PE Ratio (TTM) | 16.53 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for UTHR
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., August 03, 2022--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarter of 2021.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., July 27, 2022--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2022 financial results before the market opens on Wednesday, August 3, 2022.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & ROCK HILL, S.C., June 06, 2022--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that in partnership with 3D Systems Corporation (NYSE: DDD) it has produced the world’s most complex 3D-printed object – a human lung scaffold – and demonstrated it at the LIFE ITSELF Conference that occurred May 31 to June 3, 2022 in San Diego. The event was organized and hosted by Dr. Sanjay Gupta and Marc Hodosh and w